Southport & Formby CCG Governing Body 5 February 2020: Item 20/10 Commissioning Policies
Appendix 1 – Criteria Based Clinical Treatment Policy : Suite 3 policies – Summary of Policy Changes
Policy name |
Summary of policy changes |
Policy Document |
EIRA |
i. Botulinum Toxin A and B |
The criteria for the use of this treatment now reflects the Pan Mersey Area Prescribing Committee (APC) positions and NICE Guidance. This refers to the use of Botox for hyperhidrosis and migraine. This update to match Pan Mersey means improved access to services. |
Policy for Botulinum Toxin A & B | EIA Botox |
ii. Policy for Prostatism/Lower Urinary Symptoms in Men |
At present there are criteria in place however commissioners feel a pathway to treatment would be more appropriate therefore this update incudes a pathway to treatment. |
Policy for Prostatistm/Lower Urinary tract symptoms in men | EIA Prostatism |
iii. Secondary Care Administered Steroid Peripheral Joint Injections |
There are a number of changes in criteria and clarification around setting in which to deliver injections. |
Policy for secondary care administered steroid peripheral joint injections | EIA Joint injections |
iv. Continuous Glucose Monitoring |
It has been requested that the policy makes more specific reference to the use of continuous glucose monitoring systems for pregnant women and children based on the latest clinical evidence. |
Policy for continuous glucose monitors | EIA stage 2 CGM |
v. Insulin Pumps |
Currently CCGs follow NICE TA151, however the draft policy for insulin pumps also makes provision for patients who have had a pancreatectomy and meet the criteria in NICE TA151 as well as patients with cystic fibrosis-related diabetes (CFRD) |
Policy for continuous sub-cutaneous insulin infusion (CSII) therapy | EIA stage 2 insulin pumps |
vi. Transanal Irrigation |
Changes reflect NICE guidance and the use of electric pumps. |
Policy for transanal irrigation | EIA TAI |